Journal of Clinical and Aesthetic Dermatology最新文献

{"title":"The Role of TYK2 Inhibitors in the Pathogenesis and Treatment of Psoriasis.","authors":"Joshua Burshtein, Todd Schlesinger","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic, inflammatory condition that has a substantial effect on quality of life. Tyrosine kinase 2 (TYK2) inhibitors have emerged as a promising class of agents for treating psoriasis.</p><p><strong>Objective: </strong>To summarize the current evidence on TYK2 inhibitors and their role in the management of psoriasis.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted using a combination of the keywords \"psoriasis,\" \"tyrosine kinase,\" \"pathogenesis,\" \"mechanism of action,\" and \"emerging therapies.\" The authors reviewed all studies and included those that addressed the topic of the review.</p><p><strong>Results: </strong>TYK2 plays an integral role in the pathogenesis of psoriasis. Targeting TYK2 as a therapeutic pathway has led to significant improvement in disease severity and quality of life. Deucravacitinib was the first TYK2 inhibitor approved by the Unitefor moderate-to-severe plaque psoriasis. Zasocitinib and envudeucitinib are 2 agents currently undergoing late-stage clinical trials for psoriasis. The mechanism of action for these therapies is similar, targeting the JH2 pseudokinase domain of TYK2, but each has distinct features that differentiate their effectiveness and safety. Several other TYK2 inhibitors are in earlier development, including D-2570, ICP-488, AC-201, and TLL-018.</p><p><strong>Limitations: </strong>This review is limited by the information available in the published literature. In addition, comparisons between studies are limited as varying methodologies were used.</p><p><strong>Conclusion: </strong>TYK2 inhibition represents a significant advancement for the treatment of psoriasis. Continued research will enable optimization of these agents in managing psoriasis and related immune-mediated diseases.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 7","pages":"23-27"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recognizing Pyoderma Gangrenosum as a Rare Complication of Breast and Gynecologic Surgery.","authors":"Toan N Vu, David Cotter","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 7","pages":"8-9"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aesthetic Considerations for Preventing and Managing GLP-1 Receptor Agonist-Related Facial Aging.","authors":"Kanthi Bommareddy, Sabrina Fabi, Mariana Muniz","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for obesity and type 2 diabetes, resulting in rapid or massive weight loss (MWL) that can profoundly affect facial adipose tissue (AT) and skin homeostasis. Facial AT, comprising dermal, subcutaneous, and deep layers, plays a critical role in structural support, extracellular matrix (ECM) maintenance, and paracrine signaling to fibroblasts and keratinocytes. GLP-1 RA-MWL leads to AT depletion, with associated skin laxity, volume loss, and accelerated aging, particularly in periorbital and midfacial regions. Concurrently, improved glycemic control reduces advanced glycation end products, dampens inflammation, and preserves collagen integrity, highlighting the complex effects on the cutaneous microenvironment.</p><p><strong>Objective: </strong>To develop a regenerative, multifaceted approach for optimal aesthetic management.</p><p><strong>Results: </strong>Our proposed protocol includes multilayer fat grafting (millifat, microfat, nanofat) to restore AT and support fibroblast function, scaffolds such as calcium hydroxyapatite and poly-L-lactic acid to stimulate collagen and adipogenesis, hybrid hyaluronic acid complexes for volumization, and energy-based devices including microfocused ultrasound and fractional lasers to enhance ECM remodeling and skin tightening. Adjunctive biochemical cues such as polynucleotides, peptides, and platelet-rich plasma further promote tissue regeneration.</p><p><strong>Conclusion: </strong>A staged, individualized treatment plan, combined with lifestyle and nutritional optimization, ensures sustainable aesthetic outcomes for patients experiencing GLP-1 RA-associated facial changes.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 7","pages":"16-22"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy of Topical Trichloroacetic Acid and Superficial Cryotherapy in Resistant Alopecia Areata: A Randomized Clinical Trial.","authors":"Rania Nabil Abd-Elbaky, Ramadan M Eldahshan, Osama Elshabory, Mohamed L Elsaie","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Alopecia areata (AA) is a frequent nonscarring alopecia affecting the body or scalp, distinguished by hair loss without clinical inflammatory indicators.</p><p><strong>Objective: </strong>To compare the efficiency and safety of trichloroacetic acid (TCA), 35%, vs superficial cryotherapy in the treatment of resistant AA.</p><p><strong>Methods: </strong>In a double-armed, single-blinded, randomized clinical trial, 32 patients with resistant AA were randomized into 2 groups of 16 patients each: superficial cryotherapy group and topical TCA group. The first group was treated with superficial cryotherapy administered by spraying liquid nitrogen for 15 seconds, followed by thawing, and repeated for 2 further cycles, every 2 weeks for 3 months (6 sessions). The second group was treated with topical TCA performed once monthly for 3 months (3 sessions).</p><p><strong>Results: </strong>No statistically significant variance was discovered among the examined groups according to Severity of Alopecia Tool (SALT) score before treatment (<i>P</i>=0.93). Following treatment, a SALT score reduction from 10.93±3.90 to 7.28±3.27 was demonstrated among the cryotherapy group and from 10.81±4.91 to 4.46±2.88 in the TCA group. A more significant reduction in alopecia severity (<i>P</i><0.01) was discovered after treatment among the TCA group.</p><p><strong>Conclusion: </strong>We have demonstrated the efficacy of both treatments with a more significant result favoring TCA. Considering that it is less painful and easier to perform, superficial cryotherapy is especially worthy of application to patients with mild AA and with stable course who have difficulty with conventional treatments.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 7","pages":"28-32"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Plantar Malignant Melanoma, Subungual Melanoma, and Spitzoid Melanoma: A Case Series of Rare Pediatric Melanomas.","authors":"Aaron Cheng, Katelyn Cornelius, David Cotter, Thuy L Phung, Rodrigo Valdes Rodriguez, Emily M Becker, Katie Wiggins-Dohlvik, Richard Thomson, Aaron Sugalski","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In this article, we describe 3 distinct subtypes of pediatric melanoma with atypical clinical features and unique molecular testing, suggesting de novo tumor development, treated surgically.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 7","pages":"47-51"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing Closely Excised Nonmelanoma Skin Cancer.","authors":"Sebastian Kosasih, Chrysavgi Mavrokefalou, Shahab Shahid, Naguib El-Muttardi, Ben Miranda","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>The aim of nonmelanoma skin cancer (NMSC) excision is histologic clearance with margins of ≥1 mm, but evidence for close-margin management is scarce.</p><p><strong>Background: </strong>To compare complete, close, and incomplete excision recurrences.</p><p><strong>Methods: </strong>We performed a retrospective study of a subset of patients who underwent NMSC excision during 2020 to 2021. Lesions were grouped as complete (≥1 mm clearance), close (<1 mm), or incomplete (involved) and recurrence data were collected. Discrete data were analyzed using a χ² test.</p><p><strong>Results: </strong>There were 421 lesions comprising 194 squamous cell carcinomas (SCCs; 49%) and 227 basal cell carcinomas (BCCs; 51%) included in the analysis. The mean follow-up was 29.3 months (standard deviation: 3.2), and the recurrence rate was 5%. There was a significantly greater risk of recurrence in closely (12%) vs completely (3%) excised SCCs (χ²=4.71; degrees of freedom [df]=1; <i>P</i>=0.03); however, no difference was demonstrated between close (12%) and incompletely (12%) excised SCCs (χ²<0.05; df=1; <i>P</i>=0.98). There was no statistical difference in recurrence rates between completely (1%) and closely (3%) excised BCCs (χ²=1.08; df=1; <i>P</i>=0.30), but a difference was found between closely (3%) and incompletely (16%) excised BCCs (χ²=6.33; df=1; <i>P</i>=0.01).</p><p><strong>Limitations: </strong>Follow-up was <5 years, after which NMSCs may still recur.</p><p><strong>Conclusion: </strong>Our results support the clinical practice of treating closely excised SCCs as incomplete and treating closely excised BCCs as complete, perhaps with a follow-up period, in select cases such as when satisfying patient preference or minimising morbidity due to re-excision.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 7","pages":"41-46"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Active Shelf: A Clinician's Guide to Active Dermatologic Care for Atopic Dermatitis.","authors":"Sandi Assaf, Peter Lio","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Key therapeutic options for dermatologic care frequently extend beyond prescription medications to include evidence-based, over-the-counter (OTC) topicals that meaningfully influence disease pathophysiology. We introduce the concept of active dermatologic care (ADC), which encompasses nonprescription topical products with biologically active compounds that support and modulate key skin disease processes and can be routinely incorporated into comprehensive dermatologic care plans. We expand upon the recent concept of categorizing OTC active ingredients for acne based on their mechanisms of action and apply it to atopic dermatitis. The pathophysiologic pillars of itch, barrier dysfunction, acid mantle disruption, dysbiosis, and inflammation are each considered as potential therapeutic targets for ADC.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 7","pages":"33-37"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OX40/OX40L Costimulatory Pathway: A Potential Therapeutic Target for Allergic Contact Dermatitis?","authors":"Walter Liszewski, Naiem Issa","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>OX40 and OX40L inhibitors represent the next generation of therapies to treat atopic dermatitis. However, because to their unique mechanism, they have tremendous potential to treat allergic contact dermatitis. Although the cornerstone of allergic contact dermatitis management is allergen avoidance, it is not possible in all cases. In this article, we outline the immunology of these drugs and how they could be leveraged to treat refractory allergic contact dermatitis.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 7","pages":"38-40"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Applications of Vitamin C in Dermatology: A Systematic Review.","authors":"Tanya Boghosian, Hannah Mendez, Nazar Boghosian, Mira Sayegh, Jacob Beer, Antonella Tosti","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate clinical applications, efficacy profiles, and delivery strategies of vitamin C and its derivatives in dermatology.</p><p><strong>Methods: </strong>A systematic review of PubMed and Scopus identified studies published from 2020 onward, evaluating topical, injectable, or systemic vitamin C formulations. Of 263 screened publications, 44 met inclusion criteria. Data were extracted regarding derivative type, delivery platform, and outcomes.</p><p><strong>Results: </strong>Ascorbic acid remains the most clinically validated formulation, with low-pH stabilized systems and L-ascorbic acid, vitamin E, and ferulic acid-type complexes consistently improving photoaging, structural aging, pigmentary disorders, and periprocedural healing. Ascorbyl tetraisopalmitate shows superior lipophilic stability, benefiting pigmentary and structural aging. Tetrahexyldecyl ascorbate is preferred for sensitive skin but requires acetyl zingerone stabilization. Ascorbyl glucoside with or without arginine is well tolerated for chronic hyperpigmentation. Sodium ascorbyl phosphate improves texture and pigmentation, particularly when paired with microneedling. Bis-glyceryl ascorbate demonstrates niche utility for preventing tyrosine kinase inhibitor-associated hand-foot skin reaction. Ascorbyl palmitate and magnesium ascorbyl phosphate emulgels provide rapid pigment lightening. Across modalities, procedural delivery-microneedling, jet injection, and radiofrequency-assisted laser import-enhances penetration and clinical response. Dietary vitamin C at 40 to 80 mg per day offers modest systemic photoprotection, hydration, and wrinkle-smoothing benefits, even without overt deficiency.</p><p><strong>Limitations: </strong>Study heterogeneity and a paucity of standardized data, particularly regarding diverse phototypes, restrict direct comparison; further research is required to guide optimal dermatologic use.</p><p><strong>Conclusion: </strong>Clinical effectiveness of vitamin C depends on derivative chemistry, vehicle, pH, stabilization strategy, and delivery method. Personalized selection by skin type, treatment goals, and delivery modality is essential.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 7","pages":"10-15"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fundamentals of Dermatology Article Series: When Is Cutaneous Vasculitis \"More Than Just a Rash\"?","authors":"David Seiter, James Q Del Rosso","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cutaneous vasculitis is frequently encountered in dermatology practice and is often limited to the skin. However, a subset of patients may have associated systemic involvement affecting the renal, gastrointestinal, pulmonary, or neurologic systems. Distinguishing self-limited cutaneous disease from potentially serious systemic vasculitis can be clinically challenging, particularly in the absence of formal diagnostic guidelines. This brief report reviews factors associated with systemic involvement, including constitutional symptoms, gastrointestinal complaints, hematuria, and ulcerative or necrotic lesions. The role of laboratory evaluation, histopathology, and direct immunofluorescence in guiding risk stratification and targeted workup escalation is also discussed. A focused, evidence-based approach may help dermatology clinicians reduce diagnostic uncertainty while avoiding unnecessary testing.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 6","pages":"49-51"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}